AUA (2014, reaffirmed 2025) and EAU/ESPU (annually updated) agree on the core principles: refer around 6 months, and operate at 6-18 months (EAU/ESPU emphasizes completion by 12 months more explicitly). This piece focuses on the core of that recommendation — why this specific window — and covers the remaining details in a comparison table.
Why 6 to 18 Months
The Strongest Evidence — Damage Accumulates Over Time
There's genuine debate about the exact cellular mechanism, but the timing-outcome relationship itself is consistently confirmed across studies using entirely different methodologies.
- Histology: for each month a testis remains undescended, the risk of severe germ cell loss rises 2% and Leydig cell loss 1% (Tasian et al., 2009; 274 specimens analyzed).
- Cancer risk: prepubertal orchiopexy carries a 2- to 6-fold lower relative risk of testicular cancer than postpubertal surgery (literature synthesis cited in the AUA guideline).
- Fertility: boys who had surgery before age 10 had significantly higher rates of successful testicular sperm extraction (TESE) in adulthood than those who had it later (Kim et al., 2023, our own team's meta-analysis).
Histology, epidemiology, and clinical fertility outcomes — three independent methodologies converging on the same conclusion — is the single strongest piece of evidence behind the 6-18 month window. The pathophysiological discussion below is an attempt to understand the mechanism more precisely; it isn't a challenge to this evidence.
The Proposed Cellular Explanation
During the transient rise in gonadotropins and testosterone known as "mini-puberty," at 1 to 3 months of age, undifferentiated germ cells (gonocytes) differentiate into Ad spermatogonia (dark-nucleus immature spermatogonia), a process that broadly unfolds over the first 12 months of life — one clinical interpretation connects this timeline to why EAU/ESPU emphasizes completion by 12 months more explicitly than AUA does. That said, the point at which differentiation completes varies meaningfully from child to child, and a recent single-cell molecular study comparing human, primate, and mouse testes found that molecularly distinct subpopulations of undifferentiated spermatogonia don't map cleanly onto the classic Ad/Ap morphological categories (Shami et al., 2020) — so it's more accurate to treat Ad spermatogonia as one histological marker among several, rather than declaring them "the" fertility stem cell.
Elevated temperature is the most commonly cited reason this differentiation breaks down in an undescended testis, but the claim that "being outside the scrotum means constant exposure to core body temperature (37°C)" oversimplifies things. Direct temperature measurements found an average of roughly 34.4°C in cryptorchid testes versus 33.2°C in the normally positioned contralateral testis (Mieusset et al., 1993) — too narrow a gap to explain by heat alone. Notably, Hadziselimovic himself published a 2021 review arguing the opposite emphasis: that a deficiency in gonadotropin stimulation during mini-puberty (hypogonadotropic hypogonadism), not temperature, may be the more fundamental cause, citing clinical, genetic, and histological evidence against a temperature-centered model. In other words, there's genuine disagreement within the field about the mechanism itself.
One further proposed model holds that some residual undifferentiated germ cells acquire genetic instability and transform into a precursor lesion called germ cell neoplasia in situ (GCNIS, formerly carcinoma in situ). But residual immature germ cells are not themselves GCNIS, and an association between fetal germ cell maturation abnormalities and the origin of GCNIS is not the same as a confirmed single causal pathway from postnatal heat exposure. Skakkebaek's Testicular Dysgenesis Syndrome (TDS) hypothesis — that undescended testis, hypospadias, reduced sperm counts, and testicular cancer share a common origin in fetal testicular developmental disruption — is often cited alongside this (Skakkebaek et al., 2001), but it should be treated as a hypothesis explaining a shared developmental origin, not a proven, unified mechanism accounting for every case.
Most boys with unilateral cryptorchidism who have surgery at the right time can expect normal fertility (the risk is relatively higher with bilateral disease). That said, Hildorf et al. (2020) found that among 333 boys who had surgery within the first year of life, 20-25% showed compromised fertility potential — and this risk group was defined by already having low or absent Ad spermatogonia, or abnormal hormone markers, at the time of surgery, not by a normal count. Even perfect timing doesn't erase this risk for everyone; timely surgery is the essential first step, not the last safeguard.
Why Not Before 6 Months?
The lower bound (around 6 months) is less a pathophysiological boundary than an observation period for spontaneous descent. The vast majority of spontaneous descent happens before 6 months, and cohort data show the likelihood drops sharply after that point (Wenzler et al., 2004) — operating too early risks unnecessary surgery on a testis that would have descended on its own. It's better understood as a general observation period than an absolute rule; exceptions exist for emergencies like testicular torsion or an accompanying hernia. Anesthesia risk in very young infants is sometimes cited as a secondary consideration, though the literature's emphasis rests more on observing for spontaneous descent.
Guideline Comparison, Item by Item
| Item | AUA (2014, reaffirmed 2025) | EAU/ESPU (annually updated) |
|---|---|---|
| Referral timing | Refer if no spontaneous descent by 6 months, corrected gestational age (Statement 5) | Recommends starting treatment procedures from 6 months — effectively the same threshold |
| Bilateral non-palpable newborn | Specifies immediate evaluation to rule out a DSD, particularly congenital adrenal hyperplasia (Statement 5) | Specifies urgent, mandatory endocrine/genetic workup — both guidelines route this apart from the 6-month waiting pathway |
| Imaging before referral | Not recommended | Not recommended, citing ultrasound's low sensitivity/specificity |
| Hormone therapy — for descent | Not recommended | Not recommended — under 20% success, notes hCG's potential germ cell toxicity |
| Hormone therapy — for fertility preservation | Not addressed as a separate category | A GnRH analogue, given peri- or post-operatively, can be considered in high-risk groups (e.g., bilateral cases) — explicitly distinguished from hCG |
| Diagnosing the non-palpable testis | Laparoscopy is the standard; exam under anesthesia is the first step | States a preference for laparoscopy; notes ultrasound, CT, and MRI offer no benefit |
| Retractile testis | No treatment; annual follow-up through puberty | Same principle |
| Intra-abdominal (high) testis | Presents staged approaches such as Fowler-Stephens | Prefers a staged operation. Recent editions also mention the Shehata technique |
| UDT discovered after puberty | Statement 15 — offers orchiectomy when the contralateral testis is normal and there are very short cord vessels, marked dysmorphism, or post-pubertal age | Panel consensus explicitly recommends orchiectomy when the contralateral testis is normally positioned; orchiopexy remains the rule if palpable |
The two guidelines share the same logic on when to refer and why surgery isn't rushed before 6 months. "No later than 18 months" is a clinical consensus threshold, not a point of guaranteed safety. Hormone therapy and post-pubertal UDT are often collapsed into a flat "not recommended," but each has more differentiated guidance depending on purpose and condition.
The Clinical Workflow in Practice
- Screening. Testicular position is checked at the newborn exam or a well-child visit. Bilateral non-palpable testes or signs suggesting a DSD branch immediately to evaluation rather than the standard 6-month wait.
- Referral. Refer to pediatric urology if there's no spontaneous descent by 6 months (acquired cases are referred at the time they're discovered).
- Specialist exam. Confirm palpability. A retractile testis branches to observation right here.
- Treatment and surgery. Palpable testes go to orchiopexy; non-palpable testes get an exam under anesthesia followed by laparoscopy. Target as early as reasonable after 6 months, no later than 18 months; consider a staged approach for a high intra-abdominal testis.
- Follow-up. Track testicular position and size postoperatively.
The Gap Between Guidelines and Practice
A published guideline doesn't automatically translate into changed clinical behavior. Weiner et al. (2023, Urology Practice) compared practice data across 4 institutions and 3,293 referred patients before and after the 2014 AUA guideline was published. The median age at first evaluation (39 months, across the whole cohort) showed no significant improvement through 2015, and by 2019 had actually increased significantly (P=.03). The picture on the EAU/ESPU side is similar: a 2023 survey of 157 EUPSA members (on adherence to the 2016 edition) found 77% reported following the guideline, but substantial variation remained in actual surgical timing, hormone therapy use, and approach to the non-palpable testis (78% preferred laparoscopy versus 18% ultrasound). Guidelines set the principle; the actual decisions still depend heavily on individual clinician experience and institutional practice.
This pathophysiology, connected to the history of pathogenesis theory and prognosis, continues in For Clinicians' Undescended Testis, Part 1, with the actual surgical techniques covered in Part 2.
References
- Kolon TF, Herndon CDA, Baker LA, et al. Evaluation and Treatment of Cryptorchidism: AUA Guideline. J Urol. 2014;192(2):337-345 (last reviewed/reaffirmed 2025).
- European Association of Urology (EAU) / European Society for Paediatric Urology (ESPU). Paediatric Urology Guidelines. Annually updated; first published 2001.
- Tasian GE, Hittelman AB, Kim GE, DiSandro MJ, Baskin LS. Age at orchiopexy and testis palpability predict germ and Leydig cell loss: clinical predictors of adverse histological features of cryptorchidism. J Urol. 2009;182(4):1553-1559.
- Kim SW, Lee J, Lee TH, Kim DS, Song SH, Kim DK. Azoospermic Men with a History of Cryptorchidism Treated by Orchiopexy Have Favorable Outcomes after Testicular Sperm Extraction: A Systematic Review and Meta-Analysis. World J Mens Health. 2023;41(1):81-93.
- Thorup J, Kvist K, Clasen-Linde E, Petersen BL, Cortes D. The relation between adult dark spermatogonia and other parameters of fertility potential in cryptorchid testes. J Urol. 2013;190(4 Suppl):1566-1571.
- Hildorf S, Clasen-Linde E, Cortes D, Fossum M, Thorup J. Fertility Potential is Compromised in 20% to 25% of Boys with Nonsyndromic Cryptorchidism despite Orchiopexy within the First Year of Life. J Urol. 2020;203(4):832-840.
- Shami AN, et al. Single-Cell RNA Sequencing of Human, Macaque, and Mouse Testes Uncovers Conserved and Divergent Features of Mammalian Spermatogenesis. Dev Cell. 2020.
- Park KJ. Key Issues in Cryptorchidism Seen in Outpatient Practice. Urology Digest. 2021;2(4):135-139.
- Mieusset R, Fouda PJ, Vaysse P, Guitard J, Moscovici J, Juskiewenski S. Increase in testicular temperature in case of cryptorchidism in boys. Fertil Steril. 1993;59(6):1319-1321.
- Hadziselimovic F. Temperature is not a major factor in the differentiation of gonocytes into Ad spermatogonia and fertility outcome in congenitally cryptorchid boys. Basic Clin Androl. 2021;31:19.
- Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod. 2001;16(5):972-978.
- Wenzler DL, Bloom DA, Park JM. What is the rate of spontaneous testicular descent in infants with cryptorchidism? J Urol. 2004;171(2 Pt 1):849-851.
- Weiner H, Solomon JR, Thinnes R, et al. How Effective Was the 2014 AUA Cryptorchidism Guideline? A Multi-institutional Evaluation. Urol Pract. 2023;10(6):605-610.
- European Paediatric Surgeons' Association Survey on the Adherence to EAU/ESPU Guidelines in the Management of Undescended Testes. 2023 (online); 2024 (print).